Disease |
Disease |
Method |
Sample |
Expression pattern |
Dysfunction type |
Description |
PMID |
Source |
tumor |
N/A |
N/A |
N/A |
regulation |
An example of this mechanism is represented by the tumour suppressor gene PTEN and its pseudogene PTENP1. |
23660942 |
LncRNADisease
|
prostate cancer |
N/A |
N/A |
N/A |
regulation |
Oncogene; tumour suppressor |
24373479 |
LncRNADisease
|
cancer |
N/A |
N/A |
N/A |
regulation |
PTENP1 pseudogene belongs to the group of competing endogenous RNAs (ceRNAs). It may act as “decoy” by protecting PTEN mRNA from binding to common miRNA and therefore allowing expression of the tumor suppressor protein.? |
24757675 |
LncRNADisease
|
gastric cancer |
qPCR etc. |
cancerous gastric tissue, blood (serum) |
up-regulated |
expression |
A three-lncRNA signature, including CUDR, LSINCT-5 and PTENP1, was identified that may be potential diagnostic marker for GC. Moreover, a risk model for the serum three-lncRNA signature demonstrated that healthy samples can be distinguished from early GC samples. Three-lncRNA signature in serum was identified as diagnostic marker for GC. |
25694351 |
Lnc2Cancer
|
hepatocelluar carcinoma |
qPCR, Western blot etc. |
HCC cell lines |
down-regulated |
expression |
Here we confirmed that PTENP1 and PTEN were downregulated in several HCC cells.These data colletcively unveiled the molecular mechanisms of how PTENP1 repressed the tumorigenic properties of HCC cells and demonstrated the potential of the SB-BV hybrid vetcor for PTENP1 lncRNA modulation and HCC therapy.PTENP1 repressed the tumorigenic properties of HCC cells and demonstrated the potential of the SB-BV hybrid vector for PTENP1 lncRNA modulation and HCC therapy. |
25617127 |
Lnc2Cancer
|
|